

Corrigendum

Letter to the Editor: SUN vs BEV β IFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

M Nuijten and G Mickisch

British Journal of Cancer (2010) **102**, 1078. doi:10.1038/sj.bjc.6605613 www.bjcancer.com
© 2010 Cancer Research UK

Correction to: *British Journal of Cancer* (2010) **102**, 232–233.
doi: 10.1038/sj.bjc.6605446

The correct affiliation for Dr Nuijten is ‘Ars Accessus Medica in Amsterdam, Dorpsstraat 75 1546 LG, The Netherlands’.

Upon publication of this Letter to the Editor, it was noted that the affiliation for Dr Mark Nuijten had been presented incorrectly.